Ocular Therapeutix (OCUL) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Does the media prefer BPMC or OCUL?

In the previous week, Ocular Therapeutix had 1 more articles in the media than Blueprint Medicines. MarketBeat recorded 2 mentions for Ocular Therapeutix and 1 mentions for Blueprint Medicines. Ocular Therapeutix's average media sentiment score of 1.46 beat Blueprint Medicines' score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate BPMC or OCUL?

Blueprint Medicines presently has a consensus target price of $130.00, indicating a potential upside of 0.42%. Ocular Therapeutix has a consensus target price of $17.20, indicating a potential upside of 39.84%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	16 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Ocular Therapeutix	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, BPMC or OCUL?

Blueprint Medicines has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.

Do insiders & institutionals believe in BPMC or OCUL?

59.2% of Ocular Therapeutix shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Is BPMC or OCUL more profitable?

Blueprint Medicines has a net margin of -27.70% compared to Ocular Therapeutix's net margin of -382.51%. Blueprint Medicines' return on equity of -64.60% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-27.70%	-64.60%	-17.22%
Ocular Therapeutix	-382.51%	-71.92%	-49.36%

Which has preferable valuation & earnings, BPMC or OCUL?

Blueprint Medicines has higher revenue and earnings than Ocular Therapeutix. Blueprint Medicines is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$562.12M	14.87	-$67.09M	-$2.47	-52.41
Ocular Therapeutix	$63.72M	33.59	-$193.51M	-$1.28	-9.61

Summary

Ocular Therapeutix beats Blueprint Medicines on 10 of the 16 factors compared between the two stocks.